Logo

Genetic Technologies Settles IP Dispute with Genesis Genetics Institute

Sep 03, 2013 | staff reporter

NEW YORK (GenomeWeb News) – Genetic Technologies today announced it has settled with Genesis Genetics Institute over GTG's patent covering its non-coding DNA technology.

GTG sued Detroit-based Genesis Genetics in September in US District Court Eastern District of Michigan, Southern Division, alleging Genesis Genetics infringed on US Patent No. 5,612,179 which was assigned by an entity called Genetype AG to GTG.

The patent is at the center of a number of lawsuits that GTG has leveled at competitors alleging infringement, and in July it settled with Reproductive Genetics Institute over similar litigation. That followed a deal between GTG and Bioscientia Institute for Medical Diagnostics in late June to settle a dispute over the '179 patent.

Terms of the settlement announced today were not disclosed.

On Friday, GTG said that New York has issued a Clinical Laboratory Permit to the firm, allowing it to offer its BREVAGen test to residents of the state.

Filed under

Diagnostics
Business News
Tools & Technology
intellectual property
legal settlement
non-coding DNA
Genetic Technologies
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.